BrainsWay Invests $6M in Neurolief Following FDA Approval of Proliv™ Rx for MDD

summarizeSummary

BrainsWay completed an additional $6 million strategic investment in Neurolief Ltd., triggered by FDA Premarket Approval for Neurolief's Proliv™ Rx system for Major Depressive Disorder, expanding BrainsWay's market reach.

check_boxKey Events

• Strategic Investment Completed

  BrainsWay finalized an additional $6 million convertible loan to Neurolief Ltd., bringing total investment to $11 million.

• FDA Approval Milestone Met

  The investment was triggered by Neurolief receiving FDA Premarket Approval for its Proliv™ Rx system for Major Depressive Disorder.

• Market Expansion & Synergy

  BrainsWay's CEO highlighted that Proliv™ Rx has the potential to expand their total addressable market and complement their Deep TMS™ technology.

• Commercial Progress

  Neurolief has begun scaling commercial operations, including securing a pathway into the VA health system for Proliv™ Rx.

auto_awesomeAnalysis

This filing details BrainsWay's completion of a $6 million milestone-based convertible loan to Neurolief, following the FDA's Premarket Approval of Neurolief's Proliv™ Rx system for Major Depressive Disorder. This investment, representing over 1% of BrainsWay's market capitalization, is a significant strategic move. The FDA approval for Proliv™ Rx is a key regulatory achievement for Neurolief, validating its technology and opening new commercial pathways, including access to the VA health system. BrainsWay views this as an opportunity to expand its total addressable market and create synergies with its existing Deep TMS™ technology, potentially leading to a future acquisition given BrainsWay's call option. Investors should monitor Neurolief's commercial progress and any further updates on BrainsWay's potential acquisition of the company.